|
BMS Sales Aid for Cancer Drug Draws Untitled Letter for False Claims
Bristol-Myers Squibb (BMS) has received an untitled letter for a sales aid for breast cancer drug Ixempra that allegedly made unsupported efficacy claims and broadened the drug’s indication.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives